-Down to Earth Investigation into the business of adulteration of honey This story begins in the mustard fields of north India where beekeepers are getting ready for the next honey season. When the yellow flowers are in bloom, the bees suck the nectar and bring us goodness in the form of honey, which we then consume because of its many beneficial properties. We were alerted that beekeepers from this region and other...

-The Hindu The factories in Vetapalem are in an immediate need of mechanisation ONGOLE: The cashew industry, which has flourished for hundreds of years in Vetapalem village near Chirala town in Prakasam district, is beginning to show the first warning signs of a slump. Cashew units are reportedly struggling to sustain operations in the wake of a shortage of raw material and a skilled workforce, with fingers being pointed at the Mahatma Gandhi...

-The Times of India NEW DELHI: Around 40% of the essential medicines in India with lowest MRP are priced significantly higher than estimated production costs, an assessment by the World Health Organisation (WHO) shows highlighting the “exorbitant” profiteering by pharmaceutical companies and the scope for lowering prices of drugs. While innovative and newer drugs for cancer, hepatitis C and rare diseases are out of reach of many due to their unaffordable prices,...

-The Telegraph Call to govt to adopt 'cost-based' control The 30 per cent cap on Profit margins imposed by India’s drug pricing authority on 42 anti-cancer drugs will have a limited impact on patients’ expenses because many of these medicines’ prices remain “prohibitive”, a network of patients’ rights groups said on Saturday. The All India Drug Action Network (Aidan) said the National Pharmaceutical Pricing Authority’s cap on Profit margins in effect “legitimises” the...

-The Times of India NEW DELHI: The government has capped trade margins of 42 cancer drugs at 30% expanding the span of price control to curtail undue profiteering by chemists and drug stockists on various medicines which were so far outside price regulation. The move is expected to bring major relief to around 1.5 million cancer patients in India reeling under exponentially high treatment cost leading to heavy out-of-pocket expenditure. In a detailed...